Oral Solid Dosage Contract Manufacturing Market: By Product Type, By Release Mechanism, Capsules, Powders & Granules, By End User, and Geography
Oral Solid Dosage Contract Manufacturing Market size was valued at US$ 22,678.1 million in 2023 and is expected to grow at a significant CAGR of 6.4% during 2024 to 2030. The global market provides a detailed overview and that can be segmented by product type, by release mechanism, and end user. By product type, the market has been segmented into Tablets, Capsules, Powders & Granules (MT). The Tablets segment is likely to be the largest and fastest-growing segment in terms of product type. Based By release mechanism, the market is segmented into Tablets (Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets.
Capsules (Controlled Release, Enteric Release, and Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules). The tablets segment is expected to dominate the oral solid dosage contract manufacturing market. Based on the end user, the market has been segregated into Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, and Nutraceutical Companies. The Big Pharma or Biotech segment is expected to dominate other segments in the Oral Solid Dosage Contract Manufacturing market according to Precision Business Insights.
In September 2018, Aurobindo acquired the dermatology and oral solids businesses from Sandoz Inc. This will support Sandoz's strategy of focusing on complex generics, value-added medicines, and biosimilars to achieve sustainable and profitable growth in the U.S. over the long term.
Study Period
2024-2030Base Year
2023CAGR
5.8%Largest Market
Asia PacificFastest Growing Market
North America
Increase in the prevalence of chronic diseases such as diabetes, cardiovascular, cancers, and others is a key factor surge the growth of oral solid dosage form sales. Moreover, CMOs are offering cost-effective services, rise in R&D by the leading pharmaceutical companies, and long-term strategic alliances among the market players are immense boost to the market in the future. In contract manufacturing of oral solids, information such as product formula has to be transferred from client (innovator) companies to suppliers (CMOs) which involves the risk i.e. related to data confidentiality and exclusivity. The service provider after the completion of agreement might become the competitor for innovator for the particular product. Moreover, the buyers have to pay high switching cost to the service providers due to need for compatibility with the manufacturing equipment required that is expected to limit the growth of the contract manufacturing of oral solids market.
North America accounted for larger revenue share in global contract manufacturing of oral solids market with significant CAGR owing to presence of large number of market players in the region and long term contract manufacturing partnerships between companies and CMOs strive hard to keep up with regulatory compliance drives the growth of the market over the forecast period. Asia Europe and Asia Pacific are expected to exhibit significant growth rate over the forecast period owing to rising number of contract manufacturing organizations and benefits that are obtained to the innovator companies such as cost cuttings up to 40% to 60% fuels the growth of the market over the future years.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 22,678.1 million |
|
Market CAGR |
5.8% |
|
By Product Type |
|
|
By Release Mechanism |
|
|
By End User |
|
Download Free Sample Report
The oral solid dosage contract manufacturing market size was valued at US$ 22,678.1 million in 2023 and is expected to grow at a significant CAGR of 6.4% during 2024 to 2030.
The major players in the global oral solid dosage contract manufacturing market are ??Abbvie Inc., Alcami Corporation, Cambrex Corporation (Halo Pharma), CMIC HOLDINGS Co., LTD., Confab Laboratories Inc. CordenPharma International, GENVION Corporation, Lonza Group AG, Mayne Pharma (Metrics Contract Services), Pfizer Inc., Pharma Tech Industries, Piramal Enterprises Ltd.
North America is the fastest-growing region for Oral Solid Dosage Contract Manufacturing Market
| 1. Executive Summary |
| 2. Global Oral Solid Dosage Contract Manufacturing Market Introduction |
| 2.1. Global Oral Solid Dosage Contract Manufacturing Market Taxonomy |
| 2.2. Global Oral Solid Dosage Contract Manufacturing Market Definitions |
| 2.2.1. Product |
| 2.2.2. Release Mechanism |
| 2.2.3. End User |
| 3. Global Oral Solid Dosage Contract Manufacturing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oral Solid Dosage Contract Manufacturing Market Dynamic Factors - Impact Analysis |
| 3.6. Global Oral Solid Dosage Contract Manufacturing Market Competition Landscape |
| 4. Global Oral Solid Dosage Contract Manufacturing Market Analysis,2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis,2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oral Solid Dosage Contract Manufacturing Market, By Product, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Tablets |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Capsules |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Powders & Granules (MT) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Release Mechanism, 2018 - 2022 and Forecast, 2022 2028 (Revenue, USD Mn) |
| 6.1. Tablets |
| 6.1.1. Immediate Release |
| 6.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.1.3. Market Opportunity Analysis |
| 6.1.2. Modified Release |
| 6.1.2.1. Controlled Release |
| 6.1.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.1.3. Market Opportunity Analysis |
| 6.1.2.2. Enteric Release |
| 6.1.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.2.3. Market Opportunity Analysis |
| 6.1.2.3. Others |
| 6.1.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.3.3. Market Opportunity Analysis |
| 6.1.3. Chewable Tablets |
| 6.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3.3. Market Opportunity Analysis |
| 6.1.4. Effervescent Tablets |
| 6.1.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.4.3. Market Opportunity Analysis |
| 6.2. Capsules |
| 6.2.1. Controlled Release |
| 6.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.1.3. Market Opportunity Analysis |
| 6.2.2. Enteric Release |
| 6.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.2.3. Market Opportunity Analysis |
| 6.2.3. Others |
| 6.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3.3. Market Opportunity Analysis |
| 6.3. Powders & Granules (MT) |
| 6.3.1. Uncoated Powders & Granules |
| 6.3.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.1.3. Market Opportunity Analysis |
| 6.3.2. Coated Granules |
| 6.3.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.2.3. Market Opportunity Analysis |
| 7. Global Oral Solid Dosage Contract Manufacturing Market, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Big Pharma or Biotech |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Small & Medium Size Pharma or Biotech |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Emerging or Virtual Pharma |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Nutraceutical Companies |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User and Region, 2023 - 2029 |
| 9. North America Oral Solid Dosage Contract Manufacturing MarketAnalysis,2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Tablets |
| 9.1.2. Capsules |
| 9.1.3. Powders & Granules (MT) |
| 9.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Tablets |
| 9.2.1.1. Immediate Release |
| 9.2.1.2. Modified Release |
| 9.2.1.2.1. Controlled Release |
| 9.2.1.2.2. Enteric Release |
| 9.2.1.2.3. Others |
| 9.2.1.3. Chewable Tablets |
| 9.2.1.4. Effervescent Tablets |
| 9.2.2. Capsules |
| 9.2.2.1. Controlled Release |
| 9.2.2.2. Enteric Release |
| 9.2.2.3. Others |
| 9.2.3. Powders & Granules (MT) |
| 9.2.3.1. Uncoated Powders & Granules |
| 9.2.3.2. Coated Granules |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Big Pharma or Biotech |
| 9.3.2. Small & Medium Size Pharma or Biotech |
| 9.3.3. Emerging or Virtual Pharma |
| 9.3.4. Nutraceutical Companies |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 9.6. North America Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 10. Europe Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Tablets |
| 10.1.2. Capsules |
| 10.1.3. Powders & Granules (MT) |
| 10.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Tablets |
| 10.2.1.1. Immediate Release |
| 10.2.1.2. Modified Release |
| 10.2.1.2.1. Controlled Release |
| 10.2.1.2.2. Enteric Release |
| 10.2.1.2.3. Others |
| 10.2.1.3. Chewable Tablets |
| 10.2.1.4. Effervescent Tablets |
| 10.2.2. Capsules |
| 10.2.2.1. Controlled Release |
| 10.2.2.2. Enteric Release |
| 10.2.2.3. Others |
| 10.2.3. Powders & Granules (MT) |
| 10.2.3.1. Uncoated Powders & Granules |
| 10.2.3.2. Coated Granules |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Big Pharma or Biotech |
| 10.3.2. Small & Medium Size Pharma or Biotech |
| 10.3.3. Emerging or Virtual Pharma |
| 10.3.4. Nutraceutical Companies |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 10.6. Europe Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 11. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Tablets |
| 11.1.2. Capsules |
| 11.1.3. Powders & Granules (MT) |
| 11.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Tablets |
| 11.2.1.1. Immediate Release |
| 11.2.1.2. Modified Release |
| 11.2.1.2.1. Controlled Release |
| 11.2.1.2.2. Enteric Release |
| 11.2.1.2.3. Others |
| 11.2.1.3. Chewable Tablets |
| 11.2.1.4. Effervescent Tablets |
| 11.2.2. Capsules |
| 11.2.2.1. Controlled Release |
| 11.2.2.2. Enteric Release |
| 11.2.2.3. Others |
| 11.2.3. Powders & Granules (MT) |
| 11.2.3.1. Uncoated Powders & Granules |
| 11.2.3.2. Coated Granules |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Big Pharma or Biotech |
| 11.3.2. Small & Medium Size Pharma or Biotech |
| 11.3.3. Emerging or Virtual Pharma |
| 11.3.4. Nutraceutical Companies |
| 11.4. Country Analysis2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 11.6. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 12. Latin America Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Tablets |
| 12.1.2. Capsules |
| 12.1.3. Powders & Granules (MT) |
| 12.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Tablets |
| 12.2.1.1. Immediate Release |
| 12.2.1.2. Modified Release |
| 12.2.1.2.1. Controlled Release |
| 12.2.1.2.2. Enteric Release |
| 12.2.1.2.3. Others |
| 12.2.1.3. Chewable Tablets |
| 12.2.1.4. Effervescent Tablets |
| 12.2.2. Capsules |
| 12.2.2.1. Controlled Release |
| 12.2.2.2. Enteric Release |
| 12.2.2.3. Others |
| 12.2.3. Powders & Granules (MT) |
| 12.2.3.1. Uncoated Powders & Granules |
| 12.2.3.2. Coated Granules |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Big Pharma or Biotech |
| 12.3.2. Small & Medium Size Pharma or Biotech |
| 12.3.3. Emerging or Virtual Pharma |
| 12.3.4. Nutraceutical Companies |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 12.6. Latin America Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 13. Middle East and Africa Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Tablets |
| 13.1.2. Capsules |
| 13.1.3. Powders & Granules (MT) |
| 13.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Tablets |
| 13.2.1.1. Immediate Release |
| 13.2.1.2. Modified Release |
| 13.2.1.2.1. Controlled Release |
| 13.2.1.2.2. Enteric Release |
| 13.2.1.2.3. Others |
| 13.2.1.3. Chewable Tablets |
| 13.2.1.4. Effervescent Tablets |
| 13.2.2. Capsules |
| 13.2.2.1. Controlled Release |
| 13.2.2.2. Enteric Release |
| 13.2.2.3. Others |
| 13.2.3. Powders & Granules (MT) |
| 13.2.3.1. Uncoated Powders & Granules |
| 13.2.3.2. Coated Granules |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Big Pharma or Biotech |
| 13.3.2. Small & Medium Size Pharma or Biotech |
| 13.3.3. Emerging or Virtual Pharma |
| 13.3.4. Nutraceutical Companies |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 13.6. MEA Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2.1. ??Abbvie Inc. |
| 14.2.2. Alcami Corporation |
| 14.2.3. Cambrex Corporation (Halo Pharma) |
| 14.2.4. CMIC HOLDINGS Co., LTD. |
| 14.2.5. Confab Laboratories Inc. |
| 14.2.6. CordenPharma International |
| 14.2.7. GENVION Corporation |
| 14.2.8. Lonza Group AG |
| 14.2.9. Mayne Pharma (Metrics Contract Services) |
| 14.2.10. Pfizer Inc. |
| 14.2.11. Pharma Tech Industries |
| 14.2.12. Piramal Enterprises Ltd. |
| 14.2.13. PNP Pharmaceuticals Inc. |
| 14.2.14. ThermoFisher Scientific Inc. (Patheon N.V.) |
| 14.2.15. Tower Laboratories Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
